Touching Base

BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris

Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufact

Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s

In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kon

Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics

Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells int

Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases

More big biotech deals on the docket this week. First, Merck KGaA is buying Bio-Techne for $11.3 billion to expand its presence in high-growth life science markets. We di

Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine

We are still talking about big pharma deals and biotech fundraising in this episode. The big news this week was Parabilis Medicines’s history-making IPO. We dive into the

A Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News

In this week’s episode, we start with news that Fulcrum Therapeutics is scrapping its lead pipeline program for sickle cell disease following concerns from the FDA about

AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships

Agentic AI is growing in its applications. Google DeepMind and Edison are leveraging the growing capabilities by developing AI Scientists. These platforms are poised to s

Remembering J. Craig Venter, PhD

Craig Venter recently passed away at the age of 79 from complications following a cancer diagnosis. He was well known in both science and industry and was an integral par

AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains

Some GEN editors were in sunny San Diego covering the hottest research, trends, and products from the American Association for Cancer Research meeting. We kick things off

Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge

From designing drugs with a simple text prompt to running experiments guided by extended reality, a new wave of agentic AI is transforming the modern lab. Our editors dis

Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers

This week, agentic AI steps into the limelight buoyed by the momentum from generative AI. And there’s a new virtual cell model in town courtesy of AI-drug developer Xaira

Bacteria 4D Simulation, Safer Large Gene Insertion, uniQure Roller Coaster

A new study from the J. Craig Venter Institute simulates the complete life cycle of a minimal bacterial cell in 4D space and time at nanoscale resolution. Meanwhile, in g

AI for Scientists, FDA Reverses Course, and Advances in Cancer Therapeutics

In the industry news section of this week’s episode, we kick things off with Tamarind Bio’s efforts to develop user-friendly artificial intelligence tools for science res

Women in Science, Robotics, Automation, SLAS, and Lilly Updates

Women in Science Day (February 11) was the top of the list for discussion for GEN editors in this week’s podcast. They shared an anecdote on the history of the term “scie

Ex-CEO Behind Bars, 10x’s Clinical Ambitions, and Pharma’s AI Gambit

We kick off the very first episode of 2026 with a major legal development. This week, the former CEO of CytoDyn was sentenced to 30 months in prison, more than a year aft

Editors’ Choice: Top Stories of 2025

In the final episode of 2025, the GEN team came together to reflect on some of the stories over the last year that they each found impactful. Some of the stories were cov

Lung Organoids, Autism and Sarcopenia Insights in Mice, and a Bidding War Ends

Stories on lung organoids and autism were some of the most read this week. We kicked things off by digging into recent breakthroughs in both areas including an automated

New Nasal Vaccines, Korro Stock Dips, J&J and Merck Acquisitions, and Dyno GATC

Nasal vaccines show new promise for human papillomavirus (HPV) to address cervical cancer and whooping cough. In business news, Korro's stock craters 81% as AATD interim

uniQure Staggers at FDA, Recursion's Microglia Map, and Leadership Transitions

uniQure's “game changing” data announced in September, which showed significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy

Artificial Intelligence in the Emerald City and Targeting Colon Cancer Stem Cells 

We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay